Physician profile
Melanie Hackney
NPI 1174249874
$6,448.47
in general payments reported to CMS, 2019-2025
26 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.11 · 2023: $1,705 · 2024: $2,633 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,306 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,306.37 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $911.69 | 2022-2025 | Caplyta |
| Abbvie INC. | $720.51 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $453.28 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $438.83 | 2024-2025 | Xelstrym, Secuado |
| Otsuka America Pharmaceutical, INC. | $435.74 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $427.74 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $419.38 | 2023-2025 | Auvelity |
| Tris Pharma INC | $410.89 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $392.49 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neos Therapeutics, Lp | $282.71 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Ironshore Pharmaceuticals INC. | $254.84 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $199.66 | 2023-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $176.42 | 2025 | |
| Lundbeck LLC | $172.14 | 2023-2025 | Rexulti, Abilify Maintena, Brintellix |
| Vanda Pharmaceuticals INC. | $138.87 | 2024-2025 | Fanapt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $111.67 | 2023-2025 | Trintellix |
| Vertical Pharmaceuticals, LLC | $105.38 | 2024 | Relexxii |
| Noven Pharmaceuticals, INC. | $95.34 | 2023 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $69.03 | 2023-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $63.09 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $41.93 | 2025 | Jornay Pm |
| Tempus Ai, INC | $34.29 | 2024 | |
| Idorsia Pharmaceuticals US INC | $27.96 | 2023 | Quviviq |
| Aytu Biopharma, INC. | $24.28 | 2022 | |
| Brainsway USA INC | $21.30 | 2024 | Brainsway Deep Tms System |
| Owp Pharmaceuticals, INC. | $19.01 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Hackney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.